Zonera Hassan

Abstract An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational modifications (PTMs) with ubiquitin-like proteins, including small ubiquitin-like modifiers (SUMOs), mediate numerous processes that can contribute to the fitness and survival of cancer cells.

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype Alexander Biederstädt1, http://orcid.org/0000-0002-8485-1958Zonera Hassan2, Christian Schneeweis2, Markus Schick3, Lara Schneider4,5, Alexander Muckenhuber6, Yingfen Hong1, Gerrit Siegers1, Lisa Nilsson7, Matthias Wirth3, Zahra Dantes2, Katja Steiger6,8, Kathrin Schunck9, Steve Langston10, H-P Lenhof4, Andrea Coluccio2,11, Felix Orben2, Jolanta Slawska1, Anna Scherger1, Dieter Saur8,11, Stefan Müller9, Roland Rad8,12,...

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype Alexander Biederstädt1, Zonera Hassan2, Christian Schneeweis2, Markus Schick3, Lara Schneider4,5, Alexander Muckenhuber6, Yingfen Hong1, Gerrit Siegers1, Lisa Nilsson7, Matthias Wirth3, Zahra Dantes2, Katja Steiger6,8, Kathrin Schunck9, Steve Langston10, H-P Lenhof4, Andrea Coluccio2,11, Felix Orben2, Jolanta Slawska1, Anna Scherger1, Dieter Saur8,11, Stefan Müller9, Roland Rad8,12, Wilko Weichert6,8, Jonas Nilsson7,...